[Signed by Secretary of Health] letter of Endorsement for Dolutegravir for the second-line treatment for treatment experienced adolescents and auletes living with HIV
[Department Circular No. 2021- 0410] Inclusion of Two-Dose Inactivated Polio Vaccine (IPV) in the Philippine National Formulary (PNF)
[Department Circular No. 2021- 0400] Inclusion of Tenofovir/Lamivudine/Dolutegravir (TLD) in the Philippine National Formulary (PNF)
[Department Circular No. 2021- 0376] Interim Requirements for the Health technology Assessment (HTA) of Medical Devices
Tenofovir/Lamivudine/Dolutegravir (TLD) for treatment-naive and treatment-experienced adolescents and adults living with HIV
[Department Memorandum No. 2021- 0367] Health Technology Assessment Council’s (HTAC) Updated Recommendation on COVID-19 Vaccine Sinovac
[Department Circular No. 2021- 0331] The Health Technology Assessment Council (HTAC) releases its updated evidence summaries for COVID-19 Vaccine Assessments
